This was the big news that wasn't contained in previous announcements:
Griffith University releases data on BARD1’s SubB2M technology showing 100%specificity and sensitivity for detection of all stages of ovarian cancer.
Which is the independent validation results and a major value inflection point or huge step forward (according to Bard1) see screenshot of their 2020 presentation below.
It also gives a lot of confidence that they can develop the same thing for many other cancers
News worthy of the interest level and the current share price IMO.
Ann: Outstanding SubB2M Ovarian Cancer Test Data, page-392
-
- There are more pages in this discussion • 141 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
58.0¢ |
Change
0.015(2.65%) |
Mkt cap ! $63.96M | |||
| Open | High | Low | Value | Volume |
| 56.5¢ | 58.0¢ | 56.0¢ | $38.51K | 68.38K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2293 | 56.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 58.0¢ | 13111 | 1 |
View Market Depth
| Last trade - 15.48pm 12/07/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |